UY34201A - Compuestos de azaindol y métodos para el tratamiento de vih. - Google Patents

Compuestos de azaindol y métodos para el tratamiento de vih.

Info

Publication number
UY34201A
UY34201A UY0001034201A UY34201A UY34201A UY 34201 A UY34201 A UY 34201A UY 0001034201 A UY0001034201 A UY 0001034201A UY 34201 A UY34201 A UY 34201A UY 34201 A UY34201 A UY 34201A
Authority
UY
Uruguay
Prior art keywords
azaindol
compounds
methods
hiv treatment
hiv
Prior art date
Application number
UY0001034201A
Other languages
English (en)
Inventor
Martha Alicia De La Rosa
Brian Alvin Johns
Emile Johann Velthuisen
Weatherhead Jason
Samano Vicente
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of UY34201A publication Critical patent/UY34201A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan compuestos y sales farmacéuticamente aceptables de los mismos, sus composiciones farmacéuticas, sus métodos de preparación, y su uso para el tratamiento de infecciones virales mediadas por un miembro de la familia de retrovirus, tal como el virus de inmunodeficiencia humana (HIV).
UY0001034201A 2011-07-15 2012-07-13 Compuestos de azaindol y métodos para el tratamiento de vih. UY34201A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161508197P 2011-07-15 2011-07-15

Publications (1)

Publication Number Publication Date
UY34201A true UY34201A (es) 2013-02-28

Family

ID=47519251

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034201A UY34201A (es) 2011-07-15 2012-07-13 Compuestos de azaindol y métodos para el tratamiento de vih.

Country Status (8)

Country Link
US (1) US8609653B2 (es)
EP (1) EP2731436B1 (es)
JP (1) JP6055468B2 (es)
AR (1) AR087184A1 (es)
ES (1) ES2624984T3 (es)
TW (1) TW201317237A (es)
UY (1) UY34201A (es)
WO (1) WO2013012649A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012066442A1 (en) 2010-11-15 2012-05-24 Pfizer Limited Inhibitors of hiv replication
PL2781519T3 (pl) * 2011-11-15 2020-06-29 St Pharm Co., Ltd. Nowa przeciwwirusowa pochodna pirolopirydyny i sposób jej wytwarzania
US9163023B2 (en) 2012-07-12 2015-10-20 Viiv Healthcare Uk Limited Compounds and methods for treating HIV
TW201441197A (zh) 2013-01-31 2014-11-01 Shionogi & Co Ｈｉｖ複製抑制劑
EP2821082A1 (en) 2013-07-05 2015-01-07 Laboratoire Biodim Method of producing an inactivated lentivirus, especially HIV, vaccine, kit and method of use
EP3105236B1 (en) 2014-02-12 2017-10-18 ViiV Healthcare UK (No.5) Limited Benzothiazole macrocycles as inhibitors of human immunodeficiency virus replication
US9932353B2 (en) 2014-02-18 2018-04-03 Viiv Healthcare Uk (No. 5) Limited Imidazopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
WO2015126743A1 (en) 2014-02-18 2015-08-27 Bristol-Myers Squibb Company Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
US9409922B2 (en) 2014-02-18 2016-08-09 Bristol-Myers Squibb Company Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication
US9273067B2 (en) 2014-02-19 2016-03-01 Bristol-Myers Squibb Company Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
CN103864661A (zh) * 2014-04-01 2014-06-18 湖南华腾制药有限公司 一种2-氨基-3-氰基吡咯衍生物的合成工艺
JP6579549B2 (ja) 2014-05-16 2019-09-25 塩野義製薬株式会社 Ｈｉｖ複製阻害作用を有する３環性複素環誘導体
KR101592370B1 (ko) * 2014-06-09 2016-02-11 한국화학연구원 신규한 피롤로피리딘 유도체 및 이의 hiv 저해제로서의 용도
SI3166925T1 (en) 2014-07-08 2018-06-29 Viiv Healthcare Uk Limited Isoindoline derivatives for use in treating a viral infection
CN106536513A (zh) 2014-07-22 2017-03-22 Viiv保健英国有限公司 可用作抗病毒剂的异吲哚啉酮衍生物
CN107922423B (zh) 2015-05-29 2020-10-27 盐野义制药株式会社 具有hiv复制抑制作用的含氮三环性衍生物
JP2018520162A (ja) * 2015-07-06 2018-07-26 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体
CN107835808A (zh) * 2015-07-08 2018-03-23 Viiv保健英国第五有限公司 作为人类免疫缺陷性病毒复制的抑制剂的吡啶‑3‑基乙酸衍生物
CN107922396B (zh) * 2015-07-20 2022-08-05 建新公司 集落刺激因子-1受体(csf-1r)抑制剂
WO2018020357A1 (en) 2016-07-25 2018-02-01 Viiv Healthcare Uk Limited Indoline derivatives
AU2017405244C9 (en) * 2017-03-24 2021-03-04 St Pharm Co., Ltd. Novel pyrrolopyridine derivative, method for producing same, and use thereof
TWI748194B (zh) 2018-06-28 2021-12-01 德商菲尼克斯 Ｆｘｒ有限責任公司 含有雙環核心部分之新穎lxr調節劑
KR20220023187A (ko) * 2020-08-20 2022-03-02 에스티팜 주식회사 피롤로피리딘 유도체 및 이들의 용도
EP4267573A1 (en) 2020-12-23 2023-11-01 Genzyme Corporation Deuterated colony stimulating factor-1 receptor (csf-1r) inhibitors
EP4276101A1 (en) * 2021-01-11 2023-11-15 ST Pharm Co., Ltd. Pyrrolopyridine derivative preparation method
CN113173884B (zh) * 2021-05-06 2023-08-15 陕西师范大学 二氯二茂钛催化汉斯酯1,4-二氢吡啶类化合物合成吡啶及其衍生物的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
JP2003503386A (ja) * 1999-06-25 2003-01-28 メルク エンド カムパニー インコーポレーテッド １−（芳香族またはヘテロ芳香族置換）−３−（ヘテロ芳香族置換）−１，３−プロパンジオン類およびそれの使用
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
EP1378509A4 (en) 2001-03-19 2009-03-25 Ono Pharmaceutical Co DRUGS WITH TRIAZASPIRO ç5.5] UNDECANDERIVATES AS ACTIVE SUBSTANCE
EP1786813A2 (en) 2004-09-03 2007-05-23 Plexxikon, Inc. Bicyclic heteroaryl pde4b inhibitors
RU2503679C2 (ru) * 2007-11-15 2014-01-10 Джилид Сайенсиз, Инк. Ингибиторы репликации вируса иммунодефицита человека
EA201200631A1 (ru) 2007-11-16 2012-11-30 Джилид Сайенсиз, Инк. Ингибиторы репликации вируса иммунодефицита человека
EP2220084B1 (en) * 2007-11-16 2014-02-19 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
AU2011331301A1 (en) * 2010-11-15 2013-05-23 Katholieke Universiteit Leuven Antiviral condensed heterocyclic compounds

Also Published As

Publication number Publication date
JP2014522858A (ja) 2014-09-08
US20130018049A1 (en) 2013-01-17
WO2013012649A1 (en) 2013-01-24
EP2731436B1 (en) 2017-03-08
ES2624984T3 (es) 2017-07-18
AR087184A1 (es) 2014-02-26
JP6055468B2 (ja) 2016-12-27
US8609653B2 (en) 2013-12-17
EP2731436A4 (en) 2015-03-11
EP2731436A1 (en) 2014-05-21
TW201317237A (zh) 2013-05-01

Similar Documents

Publication Publication Date Title
UY34201A (es) Compuestos de azaindol y métodos para el tratamiento de vih.
UY34648A (es) Amidas como inhibidores de pim
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
UY34472A (es) Derivados modificados de 4-fenil-piridina
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
UY34550A (es) Bencilpirazoles sustituidos
UY34566A (es) 1,4?dihidropirimidinas 4,4?disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
UY34763A (es) Inhibidores de la agregación plaquetaria
UY34593A (es) Miméticos sintéticos de apelina para el tratamiento de falla cardiaca
UY34559A (es) Inhibidores de bromodominios
UY33925A (es) Inhibidores tricíclicos de quinasas
UY34820A (es) Compuestos tipo pirrolo-pirrolidinona
UY34145A (es) Compuestos inhibidores de metaloenzimas
UY33943A (es) Derivados espirocíclicos de isoxazolina como agentes antiparasitarios.
UY34146A (es) Compuestos inhibidores de metaloenzimas
UY34817A (es) Tienopirimidinas
UY34503A (es) ?sal de bromhidrato de pridopidina?
UY34401A (es) Métodos para el tratamiento de hcv
UY34402A (es) Métodos para el tratamiento de hcv
UY34156A (es) Compuestos inhibidores de metaloenzimas
UY34302A (es) COMPUESTOS DE HEXAHIDROPIRANO[3,4-d][1,3]TIAZIN-2- AMINA
TR201813877T4 (tr) Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler.
UY34765A (es) Compuestos novedosos.
UY34824A (es) Nucleósidos de espirooxetano de uracilo
UY34467A (es) Procedimiento para la preparación de 5-fluoro-1h-pirazolopiridinas sustituidas

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20201020